3-(2-Ethoxyphenyl)-2-(piperazin-1-ylmethyl)quinazolin-4-one

SynDRA canonical compound SYN1078491 — structure-anchored drug synonym record

Clinical phase	Phase 1/Phase 2
Primary target(s)	VDAC2 \| VDAC3
Mechanism of action	voltage-dependent anion selective channel protein inhibitor

Bioactivity evidence (ChEMBL activities table — not curator-asserted)